Choosing the Right Genome Editing Technology for Your Mouse ModelsCRISPRTARGATT™ and Beyond... (February 2017)


Highlights of this Webinar:

Using autobioluminescent cells to reduce the cost and complexity of optical imaging (November 2016)



Autobioluminescent cells use a genetically encoded synthetic luciferase cassette to continuously produce a bioluminescent signal without the need for extracellular stimulation. By encoding both a luciferase protein, as well as a short synthetic pathway capable of transforming natural intracellular products into luciferin substrates, these cells can self-modulate their bioluminescent production in response to metabolic activity levels, or autonomously enact their bioluminescent phenotype in response to intra- or extracellular events. The use of this self-directed approach to bioluminescent imaging improves upon traditional reporters such as firefly luciferase (luc) by negating the need for light activating chemical substrate addition, which reduces the cost of performance while simultaneously increasing the amount of data that can be obtained per run. This eliminates the need for sample destruction or any investigator interaction, allowing for ultra-simplistic, low-cost bioluminescent screening using existing optical imaging equipment. This webinar will discuss the capabilities and uses of autobioluminescent cells for improving existing bioluminescent imaging workflows and for developing new workflows that leverage the autonomous signal generation phenotype to gather data not available from traditional optical imaging reporter platforms.

Highlights of this webinar: 

  • An introduction to autobioluminescence
  • Autobioluminescent vs. bioluminescent imaging
  •  Using autobioluminescence for in vitro applications
  •  Using autobioluminescence for in vivo applications
  •  Autobioluminescent expression in stem cells
  •  Conclusions

ONCOREF™ Reference Standards: Application of CRISPR/Cas9 to the Generation of Isogenic Cell Lines and Reference Materials (October 2016)



CRISPR/Cas9 is rapidly enabling the development of new tools for enhancing our understanding oncogenic mutations in cancer. In order to aid in advancing cancer diagnosis and treatment, Applied StemCell has recently engineered a series of 40 isogenic cell lines that feature diverse mutations in the MAPK pathway. These mutant lines are available as isogenic pairs for applications in lead compound discovery, or as FFPE and nucleic acid reference materials for assay development. This webinar will focus on ASC’s efforts in developing these research tools, as well as applications of the materials for the advancement of cancer research.

Highlights of this talk:

  • Overview of molecular reference materials 
  • Workflow and QC for ONCOREF™ cell line generation
  • Advantages of CRISPR-engineered molecular reference standards
  • Applications of reference materials in assay development
  • Q & A

CRISPR/Cas9 Gene Editing in Blood-derived Immune Cells (July 2016)


This recorded webinar discusses Applied StemCell's efforts in fine tuning its CRISPR/Cas9 technology to improve the efficiency of gene editing in blood derived

Highlights of the talk: immune cells, such as Jurkat, K562, TF1, natural killer cell-derived cell lines and bone marrow cell lines. The talk also illustrates the potential difficulties when working with blood cells and demonstrates how Applied StemCell addresses these issues. 

  • Discrepancies in guide RNA (gRNA) activity among major blood-derived cell lines and how it affects gene editing efficiency
  • Guidelines to generate your desired mutations when available gRNAs are not ideal
  • Key steps to enhance your screening process and improve genome modification efficiency
  • Alternate solutions for engineering cell lines sensitive to DNA plasmid transfection

Generating Site-specific Transgenic Rat Models using TARGATT™ (April 2016)





This webinar introduces the TARGATT™ integrase based technology for generation of transgenic rats. The TARGATT™ platform enables very efficient insertion of large fragment DNA into a preselected, transcriptionally active locus in the rat genome. The webinar also discusses the advantages of generating transgenic rat models using this technology and the various applications that these rat models can be used in.

Highlights of the talk:

  • Introduction to TARGATT™ integrase based technology
  • How TARGATT™ technology is used to generate large fragment knock-in animal models
  • Advantages of using TARGATT™ for site-specific knock-in compared to other gene editing technologies
  • How we generate transgenic rat models using the TARGATT™ platform

How to use TARGATT™ Products for Site Specific Knock in Mouse Generation (January 2016)




Our proprietary site-specific DNA integration system, TARGATT™ lets you create site-specific transgenic mice in a more efficient and faster way compared to traditional methods. The TARGATT™ technology uses PhiC31 integrase to insert any gene of interest into a specific docking site that was pre-engineered into an intergenic and transcriptionally active genomic locus. Using our novel TARGATT™ system, a gene of interest can be inserted at a well-characterized, transcriptionally-active locus in the mouse genome with guaranteed transgene expression. Our scientists at Applied StemCell can create a TARGATT™ mouse for you, or you can purchase the animals and reagents to make your own. The video describes the TARGATT™ integrase technology for the generation of site-specific transgenic mouse models. The webinar also gives practical instructions on how to use commercially available TARGATT™ products (TARGATT™ mice, mouse embryos, transgenic kits, plasmids, and genotyping kits) for a "do-it-yourself" generation of site-specific mouse models.

Also, inquire about our white paper on Transgenic Mouse Model Generation using the TARGATT™ technology.

TARGATT™ and CRISPR/Cas9 modified induced pluripotent stem cells (iPSCs) for in vitro genetic disease modeling (December 2015)




Applied StemCell is one of the prominent providers of gene editing services to generate transgenic animal and cellular models for researchers in academia and industries. This recorded presentation showcases Applied StemCell's achievements with using CRISPR/ Cas9 and its proprietary TARGATT™ gene editing technologies to modify induced Pluripotent Stem Cells (iPSCs). The webinar also explains the need for better models of human diseases and the advantages of using of genetically engineered iPSCs as in vitro models for genetic disease modeling. With examples and case studies, we describe how we optimize protocols to improve efficiency and are able to provide high quality service for generating iPSC disease models.

Highlights of this talk:

  • Current trends in genetically modified iPSCs as disease models
  • ASC's complementary technology platforms (CRISPR & TARGATT™) used for generating site-specific, genetically modified iPSC models
  • Advantages of using genetically modified iPSCs and bottlenecks in gene editing of iPSCs
  • ASC's upgraded protocols for high efficiency gene editing in iPSCs
  • Examples of gene modification from patient/ healthy individual derived iPSCs

Creating Transgenic Mice Using TARGATT™ Technology (July 2014)




This webinar highlights research applications of the TARGATT™ site-specific gene integration system for creating transgenic mouse models more quickly and efficiently. The webinar also compares the TARGATT™ technology with other genome-editing methods, including traditional random transgenics, homologous recombination and the CRISPR/Cas9 method.

Presenter: Dr. Ruby Yanru Chen-Tsai, PhD, Co-Founder & Chief Scientific Officer, AppliedStem Cell, Inc